Up­dat­ed: Al­ny­lam scores OK for sec­ond-gen hAT­TR ther­a­py as the space heats up

The lat­est ri­val to Al­ny­lam’s drug for hered­i­tary transthyretin-me­di­at­ed (hAT­TR) amy­loi­do­sis is here — and it comes from Al­ny­lam it­self.

Four years af­ter the ground­break­ing ap­proval of On­pat­tro, the world’s first RNAi ther­a­py, the FDA has ap­proved vutrisir­an, Al­ny­lam’s next-gen­er­a­tion treat­ment for polyneu­ropa­thy of hAT­TR in adults. It will be mar­ket­ed as Amvut­tra.

Where­as On­pat­tro is ad­min­is­tered as an in­tra­venous in­jec­tion every three weeks, Amvut­tra is giv­en sub­cu­ta­neous­ly once every three months.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER